Serotonergic nerve fibers in l-DOPA-derived dopamine release and dyskinesia

Neuroscience

Volumn 260, Issue , 2014, Pages 73-86

  Nevalainen, N ^a   Af Bjerken S ^a   Gerhardt, G A ^b   Stromberg I ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

5 HT; Dyskinesia; Fluoxetine; In vivo chronoamperometry; L DOPA; WAY 100 635

Indexed keywords

DOPAMINE; FLUOXETINE; LEVODOPA; SEROTONIN 1A RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DENSITY; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DYSKINESIA; FEMALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; SEROTONINERGIC NERVE CELL; SEROTONINERGIC SYSTEM; SEROTONINERGIC TRANSMISSION;

5,7-DHT; 5,7-DIHYDROXYTRYPTAMINE; 5-HT; 6-HYDROXYDOPAMINE; 6-OHDA; ABNORMAL INVOLUNTARY MOVEMENT; AIM; ANALYSIS OF VARIANCE; ANOVA; DYSKINESIA; FLUOXETINE; IN VIVO CHRONOAMPEROMETRY; L-DOPA; L-DOPA-INDUCED DYSKINESIA; LATERAL GANGLIONIC EMINENCE; LGE; LID; PBS; PHOSPHATE-BUFFERED SALINE; SEROTONIN; SEROTONIN TRANSPORTER; SERT; TH; TYROSINE HYDROXYLASE; WAY-100 635;

ANIMALS; CORPUS STRIATUM; DOPAMINE; DYSKINESIA, DRUG-INDUCED; FEMALE; FLUOXETINE; LEVODOPA; NERVE FIBERS; RATS; RATS, SPRAGUE-DAWLEY; SEROTONERGIC NEURONS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 84891960316     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.12.029     Document Type: Article

References (78)

1. Ahlskog J.E., Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001, 16:448-458.
2. Antonelli T., Fuxe K., Tomasini M.C., Bartoszyk G.D., Seyfried C.A., Tanganelli S., Ferraro L. Effects of sarizotan on the corticostriatal glutamate pathways. Synapse 2005, 58:193-199.
3. Arai R., Karasawa N., Geffard M., Nagatsu I. l-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study. Neurosci Lett 1995, 195:195-198.
4. Arai R., Karasawa N., Nagatsu I. Aromatic l-amino acid decarboxylase is present in serotonergic fibers of the striatum of the rat. A double-labeling immunofluorescence study. Brain Res 1996, 706:177-179.
5. Aron Badin R., Spinnewyn B., Gaillard M.C., Jan C., Malgorn C., Van Camp N., Dolle F., Guillermier M., Boulet S., Bertrand A., Savasta M., Auguet M., Brouillet E., Chabrier P.E., Hantraye P. IRC-082451, a novel multitargeting molecule, reduces l-DOPA-induced dyskinesias in MPTP Parkinsonian primates. PloS one 2013, 8:e52680.
6. Bara-Jimenez W., Bibbiani F., Morris M.J., Dimitrova T., Sherzai A., Mouradian M.M., Chase T.N. Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov Disord 2005, 20:932-936.
7. Bartholini G., Da Prada M., Pletscher A. Decrease of cerebral 5-hydroxytryptamine by 3,4-dihydroxyphenylalanine after inhibition of extracerebral decarboxylase. J Pharm Pharmacol 1968, 20:228-229.
8. Bedard C., Wallman M.J., Pourcher E., Gould P.V., Parent A., Parent M. Serotonin and dopamine striatal innervation in Parkinson's disease and Huntington's chorea. Parkinsonism Relat Disord 2011, 17:593-598.
9. Bezard E., Olanow C.W., Obeso J.A. Levodopa-induced dyskinesias in the absence of nigrostriatal degeneration. Mov Disord 2013, 28:1023-1024.
10. Bezard E., Tronci E., Pioli E.Y., Li Q., Porras G., Björklund A., Carta M. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Mov Disord 2013, 28:1088-1096.
11. Bibbiani F., Oh J.D., Chase T.N. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 2001, 57:1829-1834.
12. Bishop C., George J.A., Buchta W., Goldenberg A.A., Mohamed M., Dickinson S.O., Eissa S., Eskow Jaunarajs K.L. Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats. Eur J Neurosci 2012, 36:2839-2848.
13. Bonifati V., Fabrizio E., Cipriani R., Vanacore N., Meco G. Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol 1994, 17:73-82.
14. Borah A., Mohanakumar K.P. Long-term l-DOPA treatment causes indiscriminate increase in dopamine levels at the cost of serotonin synthesis in discrete brain regions of rats. Cell Mol Neurobiol 2007, 27:985-996.
15. Borah A., Mohanakumar K.P. l-DOPA induced-endogenous 6-hydroxydopamine is the cause of aggravated dopaminergic neurodegeneration in Parkinson's disease patients. Med Hypotheses 2012, 79:271-273.
16. Carlsson T., Carta M., Munoz A., Mattsson B., Winkler C., Kirik D., Bjorklund A. Impact of grafted serotonin and dopamine neurons on development of l-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain 2009, 132:319-335.
17. Carta M., Carlsson T., Kirik D., Björklund A. Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007, 130:1819-1833.
18. Carta M., Carlsson T., Munoz A., Kirik D., Bjorklund A. Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's disease. Mov Disord 2010, 25(Suppl 1):S174-S179.
19. Cenci M.A., Lundblad M. Post- versus presynaptic plasticity in l-DOPA-induced dyskinesia. J Neurochem 2006, 99:381-392.
20. Cenci M.A., Lundblad M. Ratings ofl-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr Protoc Neurosci 2007, 41(9):1-9. Chapter 9:Unit 9.25.
21. Chung K.A., Carlson N.E., Nutt J.G. Short-term paroxetine treatment does not alter the motor response to levodopa in PD. Neurology 2005, 64:1797-1798.
22. Conti M.M., Ostock C.Y., Lindenbach D., Goldenberg A.A., Kampton E., Dell'isola R., Katzman A.C., Bishop C. Effects of prolonged selective serotonin reuptake inhibition on the development and expression of l-DOPA-induced dyskinesia in hemi-parkinsonian rats. Neuropharmacology 2013, 77C:1-8.
23. de la Fuente-Fernandez R., Sossi V., Huang Z., Furtado S., Lu J.Q., Calne D.B., Ruth T.J., Stoessl A.J. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004, 127:2747-2754.
24. DeFelipe J., Arellano J.I., Gomez A., Azmitia E.C., Munoz A. Pyramidal cell axons show a local specialization for GABA and 5-HT inputs in monkey and human cerebral cortex. J Comp Neurol 2001, 433:148-155.
25. Dupre K.B., Ostock C.Y., Eskow Jaunarajs K.L., Button T., Savage L.M., Wolf W., Bishop C. Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats. Exp Neurol 2011, 229:288-299.
26. Durif F., Vidailhet M., Bonnet A.M., Blin J., Agid Y. Levodopa-induced dyskinesias are improved by fluoxetine. Neurology 1995, 45:1855-1858.
27. Eskow K.L., Dupre K.B., Barnum C.J., Dickinson S.O., Park J.Y., Bishop C. The role of the dorsal raphe nucleus in the development, expression, and treatment of l-dopa-induced dyskinesia in hemiparkinsonian rats. Synapse 2009, 63:610-620.
28. Eskow Jaunarajs K.L., George J.A., Bishop C. l-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease. Neuroscience 2012, 218:243-256.
29. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000, 47:S2-9. discussion S9-11.
30. Gerhardt G.A., Oke A.F., Nagy G., Moghaddam B., Adams R.N. Nafion-coated electrodes with high selectivity for CNS electrochemistry. Brain Res 1984, 290:390-395.
31. Gil S., Park C., Lee J., Koh H. The roles of striatal serotonin and L -amino-acid decarboxylase on l-DOPA-induced dyskinesia in a hemiparkinsonian rat model. Cell Mol Neurobiol 2010, 30:817-825.
32. Gobert A., Rivet J.M., Audinot V., Newman-Tancredi A., Cistarelli L., Millan M.J. Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release. Neuroscience 1998, 84:413-429.
33. Goetz C.G., Damier P., Hicking C., Laska E., Muller T., Olanow C.W., Rascol O., Russ H. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord 2007, 22:179-186.
34. Gregoire L., Samadi P., Graham J., Bedard P.J., Bartoszyk G.D., Di Paolo T. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of l-dopa in parkinsonian monkeys. Parkinsonism Relat Disord 2009, 15:445-452.
35. Hoffman A.F., Gerhardt G.A. In vivo electrochemical studies of dopamine clearance in the rat substantia nigra: effects of locally applied uptake inhibitors and unilateral 6-hydroxydopamine lesions. J Neurochem 1998, 70:179-189.
36. Hollister A.S., Breese G.R., Mueller R.A. Role of monoamine neural systems in l-dihydroxyphenylalanine-stimulated activity. J Pharmacol Exp Ther 1979, 208:37-43.
37. Hornykiewicz O. Brain monoamines and Parkinsonism. Psychopharmacol Bull 1975, 11:34-35.
38. Hudson J.L., van Horne C.G., Stromberg I., Brock S., Clayton J., Masserano J., Hoffer B.J., Gerhardt G.A. Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res 1993, 626:167-174.
39. Huot P., Johnston T.H., Visanji N.P., Darr T., Pires D., Hazrati L.N., Brotchie J.M., Fox S.H. Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease. Mov Disord 2012, 27:735-742.
40. Iravani M.M., Tayarani-Binazir K., Chu W.B., Jackson M.J., Jenner P. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with increased motor disability. J Pharmacol Exp Ther 2006, 319:1225-1234.
41. Jenner P.G., Brin M.F. Levodopa neurotoxicity: experimental studies versus clinical relevance. Neurology 1998, 50:S39-43. discussion S44-38.
42. Jenner P., Sheehy M., Marsden C.D. Noradrenaline and 5-hydroxytryptamine modulation of brain dopamine function: implications for the treatment of Parkinson's disease. Br J Clin Pharmacol 1983, 15(Suppl 2). 277S-289S.
43. Kannari K., Yamato H., Shen H., Tomiyama M., Suda T., Matsunaga M. Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered l-DOPA in the striatum with nigrostriatal denervation. J Neurochem 2001, 76:1346-1353.
44. Kannari K., Shen H., Arai A., Tomiyama M., Baba M. Reuptake of l-DOPA-derived extracellular dopamine in the striatum with dopaminergic denervation via serotonin transporters. Neurosci Lett 2006, 402:62-65.
45. Kapur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996, 153:466-476.
46. Kish S.J., Tong J., Hornykiewicz O., Rajput A., Chang L.J., Guttman M., Furukawa Y. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 2008, 131:120-131.
47. Kitaichi Y., Inoue T., Nakagawa S., Boku S., Kakuta A., Izumi T., Koyama T. Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats. Eur J Pharmacol 2010, 647:90-96.
48. Kuan W.L., Zhao J.W., Barker R.A. The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. Psychopharmacology (Berl) 2008, 197:279-293.
49. Larsen M.B., Sonders M.S., Mortensen O.V., Larson G.A., Zahniser N.R., Amara S.G. Dopamine transport by the serotonin transporter: a mechanistically distinct mode of substrate translocation. J Neurosci 2011, 31:6605-6615.
50. Lindgren H.S., Andersson D.R., Lagerkvist S., Nissbrandt H., Cenci M.A. l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J Neurochem 2010, 112:1465-1476.
51. Lundblad M., Af Bjerkén S., Cenci M.A., Pomerleau F., Gerhardt G.A., Strömberg I. Chronic intermittent l-DOPA treatment induces changes in dopamine release. J Neurochem 2009, 108:998-1008.
52. Maeda T., Nagata K., Yoshida Y., Kannari K. Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA. Brain Res 2005, 1046:230-233.
53. Mignon L.J., Wolf W.A. 8-hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson's disease. Neuroreport 2005, 16:699-703.
54. Muller T. Dopaminergic substitution in Parkinson's disease. Expert Opin Pharmacother 2002, 3:1393-1403.
55. Muñoz A., Li Q., Gardoni F., Marcello E., Qin C., Carlsson T., Kirik D., Di Luca M., Björklund A., Bezard E., Carta M. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of l-DOPA-induced dyskinesia. Brain 2008, 131:3380-3394.
56. Nahimi A., Holtzermann M., Landau A.M., Simonsen M., Jakobsen S., Alstrup A.K., Vang K., Moller A., Wegener G., Gjedde A., Doudet D.J. Serotonergic modulation of receptor occupancy in rats treated with l-DOPA after unilateral 6-OHDA lesioning. J Neurochem 2012, 120:806-817.
57. Navailles S., Bioulac B., Gross C., De Deurwaerdere P. Serotonergic neurons mediate ectopic release of dopamine induced by l-DOPA in a rat model of Parkinson's disease. Neurobiol Dis 2010, 38:136-143.
58. Navailles S., Bioulac B., Gross C., De Deurwaerdère P. Chronic l-DOPA therapy alters central serotonergic function and l-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease. Neurobiol Dis 2011, 41:585-590.
59. Nevalainen N., Af Bjerkén S., Lundblad M., Gerhardt G.A., Strömberg I. Dopamine release from serotonergic nerve fibers is reduced in l-DOPA-induced dyskinesia. J Neurochem 2011, 118:12-23.
60. Nirenberg M.J., Liu Y., Peter D., Edwards R.H., Pickel V.M. The vesicular monoamine transporter 2 is present in small synaptic vesicles and preferentially localizes to large dense core vesicles in rat solitary tract nuclei. Proc Natl Acad Sci U S A 1995, 92:8773-8777.
61. Olanow C.W., Damier P., Goetz C.G., Mueller T., Nutt J., Rascol O., Serbanescu A., Deckers F., Russ H. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol 2004, 27:58-62.
62. Olijslagers J.E., Werkman T.R., McCreary A.C., Kruse C.G., Wadman W.J. Modulation of midbrain dopamine neurotransmission by serotonin, a versatile interaction between neurotransmitters and significance for antipsychotic drug action. Curr Neuropharmacol 2006, 4:59-68.
63. Ostock C.Y., Dupre K.B., Jaunarajs K.L., Walters H., George J., Krolewski D., Walker P.D., Bishop C. Role of the primary motor cortex in l-dopa-induced dyskinesia and its modulation by 5-HT1A receptor stimulation. Neuropharmacology 2011, 61:753-760.
64. Pons R., Syrengelas D., Youroukos S., Orfanou I., Dinopoulos A., Cormand B., Ormazabal A., Garzia-Cazorla A., Serrano M., Artuch R. Levodopa-induced dyskinesias in tyrosine hydroxylase deficiency. Mov Disord 2013, 28:1058-1063.
65. Riahi G., Morissette M., Levesque D., Rouillard C., Samadi P., Parent M., Paolo T.D. Effect of chronic l-DOPA treatment on 5-HT(1A) receptors in parkinsonian monkey brain. Neurochem Int 2012, 61:1160-1171.
66. Rollema H., Lu Y., Schmidt A.W., Sprouse J.S., Zorn S.H. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry 2000, 48:229-237.
67. Roth B.L. Multiple serotonin receptors: clinical and experimental aspects. Ann Clin Psychiatry 1994, 6:67-78.
68. Rylander D., Parent M., O'Sullivan S.S., Dovero S., Lees A.J., Bezard E., Descarries L., Cenci M.A. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol 2010, 68:619-628.
69. Sakaue M., Somboonthum P., Nishihara B., Koyama Y., Hashimoto H., Baba A., Matsuda T. Postsynaptic 5-hydroxytryptamine(1A) receptor activation increases in vivo dopamine release in rat prefrontal cortex. Br J Pharmacol 2000, 129:1028-1034.
70. Spinnewyn B., Mautino G., Marin J.G., Rocher M.N., Grandoulier A.S., Ferrandis E., Auguet M., Chabrier P.E. BN82451 attenuates l-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease. Neuropharmacology 2011, 60:692-700.
71. Strömberg I. Intraocular grafting. Neuromethods neural transplantation methods 1999, vol. 36:149-167. Human Press, New Jersey.
72. Strömberg I., van Horne C., Bygdeman M., Weiner N., Gerhardt G.A. Function of intraventricular human mesencephalic xenografts in immunosuppressed rats: an electrophysiological and neurochemical analysis. Exp Neurol 1991, 112:140-152.
73. Tanaka H., Kannari K., Maeda T., Tomiyama M., Suda T., Matsunaga M. Role of serotonergic neurons in l-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 1999, 10:631-634.
74. Tanda G., Carboni E., Frau R., Di Chiara G. Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential?. Psychopharmacology (Berl) 1994, 115:285-288.
75. Troiano A.R., de la Fuente-Fernandez R., Sossi V., Schulzer M., Mak E., Ruth T.J., Stoessl A.J. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology 2009, 72:1211-1216.
76. Winkler C., Kirik D., Bjorklund A., Cenci M.A. l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 2002, 10:165-186.
77. Yamada H., Aimi Y., Nagatsu I., Taki K., Kudo M., Arai R. Immunohistochemical detection of l-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats. Neurosci Res 2007, 59:1-7.
78. Zeng B.Y., Iravani M.M., Jackson M.J., Rose S., Parent A., Jenner P. Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia. Neurobiol Dis 2010, 40:599-607.